• Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)

This chart shows the closing price for MDGS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Medigus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDGS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDGS

Analyst Price Target is $0.00
This price target is based on 1 analysts offering 12 month price targets for Medigus in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for MDGS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Medigus. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/12/2023AegisReiterated RatingBuyLow
10/22/2020AegisInitiated CoverageBuy$90.00Medium
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/22/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/22/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/21/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/21/2023
  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/19/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/20/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Medigus logo
Medigus Ltd., a technology-based company, provides medical-related devices and products in the United States, Europe, Asia, Israel, and internationally. The company operates through Corporate, E-commerce, Online Advertising & Internet Traffic Routing, Online Event Management, and Others segments. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it provides digital advertising platform; and operates online stores for the sale of various consumer products on the Amazon online marketplace, as well as an online event management and ticketing platform. Further, the company develops, produces, and markets miniaturized imaging equipment, and visualization solutions; electric vehicles; and wireless vehicle battery charging technologies. Medigus Ltd. was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $2.75
Low: $2.18
High: $3.11

52 Week Range

Now: N/A

Volume

28,869 shs

Average Volume

20,006 shs

Market Capitalization

$3.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Medigus?

The following Wall Street sell-side analysts have issued stock ratings on Medigus in the last twelve months: Aegis.
View the latest analyst ratings for MDGS.

What is the current price target for Medigus?

0 Wall Street analysts have set twelve-month price targets for Medigus in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Medigus in the next year.
View the latest price targets for MDGS.

What is the current consensus analyst rating for Medigus?

Medigus currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MDGS will outperform the market and that investors should add to their positions of Medigus.
View the latest ratings for MDGS.

What other companies compete with Medigus?

How do I contact Medigus' investor relations team?

Medigus' physical mailing address is Building 7A, Omer Industrial Park, Pob 3030, Omer 8496500. The company's listed phone number is 972-73-370-4691 and its investor relations email address is [email protected]. The official website for Medigus is www.medigus.com. Learn More about contacing Medigus investor relations.